Nisa Investment Advisors LLC Cuts Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nisa Investment Advisors LLC reduced its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 41.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,867 shares of the company's stock after selling 8,476 shares during the period. Nisa Investment Advisors LLC's holdings in Janux Therapeutics were worth $635,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics in the fourth quarter worth $139,000. Franklin Resources Inc. grew its stake in shares of Janux Therapeutics by 64.5% in the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock worth $937,000 after acquiring an additional 7,442 shares during the last quarter. Virtu Financial LLC lifted its holdings in shares of Janux Therapeutics by 48.0% during the third quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock valued at $339,000 after purchasing an additional 2,419 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of Janux Therapeutics during the third quarter valued at $940,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock valued at $30,107,000 after purchasing an additional 38,490 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX traded down $1.31 during trading on Friday, hitting $43.48. The company had a trading volume of 681,147 shares, compared to its average volume of 1,068,595. The stock has a 50 day simple moving average of $51.60 and a 200 day simple moving average of $48.41. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $71.71. The firm has a market capitalization of $2.28 billion, a P/E ratio of -37.16 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. The firm's quarterly revenue was down 82.6% compared to the same quarter last year. As a group, analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $51.60, for a total value of $1,290,000.00. Following the sale, the chief executive officer now owns 257,054 shares of the company's stock, valued at $13,263,986.40. This represents a 8.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 83,334 shares of company stock valued at $4,731,520 over the last quarter. 29.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on JANX shares. Leerink Partners upped their price target on Janux Therapeutics from $79.00 to $91.00 and gave the company an "outperform" rating in a report on Tuesday, December 3rd. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Scotiabank upped their price target on Janux Therapeutics from $42.00 to $62.00 and gave the company a "sector perform" rating in a report on Wednesday, December 4th. Finally, HC Wainwright upped their price target on Janux Therapeutics from $63.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $89.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.